Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (AVIR) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · AVIR · as of Jun 8, 2026
Activity summary
Buy transactions
4
P-Purchase only
Sell transactions
1
12 Months
Buy/Sell ratio
4.00
Buy/Sell (by trades)
Overall sentiment
Atea Pharmaceuticals, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
AVIR insider buying and selling by quarter
AVIR insider selling · AVIR insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · AVIR ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
AVIR executive sell shares · AVIR board member insider trading · AVIR insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 18, 2025 | Murphy Polly A. Director | Purchase | 6,100 | $25K | Form 4 |
| Mar 11, 2026 | Corcoran Andrea See Remarks | Option | 60,000 | $74K | Form 4 |
| Jan 31, 2026 | Horga Maria Arantxa Chief Medical Officer | Option | 51,283 | — | Form 4 |
| Jan 31, 2026 | Horga Maria Arantxa Chief Medical Officer | Other | 16,073 | $68K | Form 4 |
| Jan 31, 2026 | Vavricka John Chief Commercial Officer | Option | 42,083 | — | Form 4 |
| Jan 31, 2026 | Vavricka John Chief Commercial Officer | Other | 11,570 | $49K | Form 4 |
| Jan 31, 2026 | Hammond Janet MJ Chief Development Officer | Option | 58,050 | — | Form 4 |
| Jan 31, 2026 | Hammond Janet MJ Chief Development Officer | Other | 14,136 | $60K | Form 4 |
| Jan 31, 2026 | Corcoran Andrea See Remarks | Option | 54,866 | — | Form 4 |
| Jan 31, 2026 | Corcoran Andrea See Remarks | Other | 16,104 | $68K | Form 4 |
| Feb 3, 2026 | Sommadossi Jean-Pierre President, CEO, and Chairman · Director | Option | 300,000 | $372K | Form 4 |
| Jan 31, 2026 | Sommadossi Jean-Pierre President, CEO, and Chairman · Director | Option | 272,983 | — | Form 4 |
| Jan 31, 2026 | Sommadossi Jean-Pierre President, CEO, and Chairman · Director | Other | 106,093 | $450K | Form 4 |
| Jan 31, 2026 | Foster Wayne EVP, Chief Accounting Officer | Option | 41,333 | — | Form 4 |
| Jan 31, 2026 | Foster Wayne EVP, Chief Accounting Officer | Other | 12,132 | $51K | Form 4 |
| Jun 20, 2025 | Murphy Polly A. Director | Option | 29,600 | — | Form 4 |
| Jun 20, 2025 | BERGER FRANKLIN M Director | Option | 29,600 | — | Form 4 |
| Jun 20, 2025 | Duncan Barbara Gayle Director | Option | 29,600 | — | Form 4 |
| Jun 20, 2025 | Polsky Bruce Director | Option | 29,600 | — | Form 4 |
| Jun 20, 2025 | Adams Jerome M. Director | Option | 29,600 | — | Form 4 |
| Jun 20, 2025 | Lucidi Bruno Director | Option | 29,600 | — | Form 4 |
| Jan 31, 2025 | Hammond Janet MJ Chief Development Officer | Award | 11,250 | — | Form 4 |
| Jan 31, 2025 | Hammond Janet MJ Chief Development Officer | Option | 46,800 | — | Form 4 |
| Jan 31, 2025 | Hammond Janet MJ Chief Development Officer | Other | 14,134 | $43K | Form 4 |
| Jan 31, 2025 | Vavricka John Chief Commercial Officer | Award | 8,750 | — | Form 4 |
Horga Maria Arantxa
Chief Medical Officer
Date
Jan 31
Shares
51,283
Price
—
Value
—
Horga Maria Arantxa
Chief Medical Officer
Date
Jan 31
Shares
16,073
Price
$4.24
Value
$68K
Vavricka John
Chief Commercial Officer
Date
Jan 31
Shares
11,570
Price
$4.24
Value
$49K
Hammond Janet MJ
Chief Development Officer
Date
Jan 31
Shares
58,050
Price
—
Value
—
Hammond Janet MJ
Chief Development Officer
Date
Jan 31
Shares
14,136
Price
$4.24
Value
$60K
Sommadossi Jean-Pierre
President, CEO, and Chairman · Director
Date
Feb 3
Shares
300,000
Price
$1.24
Value
$372K
Sommadossi Jean-Pierre
President, CEO, and Chairman · Director
Date
Jan 31
Shares
272,983
Price
—
Value
—
Sommadossi Jean-Pierre
President, CEO, and Chairman · Director
Date
Jan 31
Shares
106,093
Price
$4.24
Value
$450K
Foster Wayne
EVP, Chief Accounting Officer
Date
Jan 31
Shares
41,333
Price
—
Value
—
Foster Wayne
EVP, Chief Accounting Officer
Date
Jan 31
Shares
12,132
Price
$4.24
Value
$51K
Hammond Janet MJ
Chief Development Officer
Date
Jan 31
Shares
11,250
Price
—
Value
—
Hammond Janet MJ
Chief Development Officer
Date
Jan 31
Shares
46,800
Price
—
Value
—
Hammond Janet MJ
Chief Development Officer
Date
Jan 31
Shares
14,134
Price
$3.06
Value
$43K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About AVIR insider trading
AVIR insider trades
Atea Pharmaceuticals, Inc. (AVIR) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Corcoran Andrea (See Remarks), Sommadossi Jean-Pierre (President, CEO, and Chairman · Director), Horga Maria Arantxa (Chief Medical Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. AVIR insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Atea Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
AVIR insider trading · 5 questionsThe insiders of Atea Pharmaceuticals, Inc. (AVIR) include executives and directors such as Corcoran Andrea (See Remarks), Sommadossi Jean-Pierre (President, CEO, and Chairman · Director), Horga Maria Arantxa (Chief Medical Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026